Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Shattuck Labs, Inc. (STTK : NSDQ)

• Company Description    Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States. Number of Employees: 85

• Price / Volume Information    Yesterday's Closing Price: $2.98 Daily Weekly Monthly 20 Day Moving Average: 205,231 shares Shares Outstanding: 42.38 (millions) Market Capitalization: $126.29 (millions) Beta: 2.44 52 Week High: $31.23 52 Week Low: $2.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.36% -8.05% 12 Week -42.69% -37.00% Year To Date -64.98% -55.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 W. 5TH STREET SUITE 1200 - AUSTIN,TX 78701 USA ph: 512-900-4690 fax: - investorrelations@shattucklabs.com http://www.shattucklabs.com

• General Corporate Information    Officers Taylor Schreiber - Chief Executive Officer and Director George Golumbeski - Chairman Andrew R. Neill - Andrew R. Neill Helen M. Boudreau - Director Neil Gibson - Director Peer Information Shattuck Labs, Inc. (CORR.) Shattuck Labs, Inc. (RSPI) Shattuck Labs, Inc. (CGXP) Shattuck Labs, Inc. (BGEN) Shattuck Labs, Inc. (GTBP) Shattuck Labs, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 82024L103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 42.38 Most Recent Split Date: (:1) Beta: 2.44 Market Capitalization: $126.29 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.51 Price/Cash Flow: - Price / Sales: 13.69 EPS Growth vs. Year Ago Period: -107.14% vs. Previous Quarter: -422.22% Sales Growth vs. Year Ago Period: 2,141.28% vs. Previous Quarter: 1,483.05% ROE 03/31/22 - -21.79 12/31/21 - -16.23 09/30/21 - -22.61 ROA 03/31/22 - -19.17 12/31/21 - -14.17 09/30/21 - -19.64 Current Ratio 03/31/22 - 15.16 12/31/21 - 11.73 09/30/21 - 15.21 Quick Ratio 03/31/22 - 15.17 12/31/21 - 11.72 09/30/21 - 15.21 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -207.91 12/31/21 - -149.83 09/30/21 - -5,061.13 Book Value 03/31/22 - 5.87 12/31/21 - 6.43 09/30/21 - 6.20 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©